Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Mar;39(3):720–724. doi: 10.1128/AAC.39.3.720

Successful treatment of Pneumocystis carinii Pneumonia in mice with benanomicin A (ME1451).

A Yasuoka 1, S Oka 1, K Komuro 1, H Shimizu 1, K Kitada 1, Y Nakamura 1, S Shibahara 1, T Takeuchi 1, S Kondo 1, K Shimada 1, et al.
PMCID: PMC162611  PMID: 7793879

Abstract

Benanomicin A (BNM-A) has antimycotic activities via binding to mannan in the cell walls of fungi. Anti-Pneumocystis carinii activity of the agent was examined in the P. carinii-infected BALB/c nu/nu female mouse model because P. carinii also possesses mannan in the membranes. The infected mice were treated with intraperitoneal injections of six doses of BNM-A (1, 2.5, 5, 10, 30, and 100 mg/kg of body weight), 4 mg of pentamidine isethionate per kg, 100 mg of sulfamethoxazole per kg combined with 20 mg of trimethoprim per kg (co-trimoxazole), or saline for 21 days. Each dosage group consisted of 10 mice. During treatment, five mice in the control group (saline) died, whereas 8 to 10 mice in all treatment groups survived. Almost the same efficacies were obtained for the groups treated with 5 mg or more and 10 mg or more of BNM-A per kg regarding the weight and number, respectively, of cysts found in the lungs as were obtained for the groups treated with pentamidine isethionate and co-trimoxazole. Overall, a dose of 10 mg of BNM-A per kg was effective against P. carinii pneumonia infection in the mice. Thus, BNM-A is a good candidate for a novel treatment for P. carinii pneumonia as a compound with a new mechanism of action against P. carinii.

Full Text

The Full Text of this article is available as a PDF (765.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allegra C. J., Chabner B. A., Tuazon C. U., Ogata-Arakaki D., Baird B., Drake J. C., Simmons J. T., Lack E. E., Shelhamer J. H., Balis F. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1987 Oct 15;317(16):978–985. doi: 10.1056/NEJM198710153171602. [DOI] [PubMed] [Google Scholar]
  2. Atzori C., Bruno A., Chichino G., Bombardelli E., Scaglia M., Ghione M. Activity of bilobalide, a sesquiterpene from Ginkgo biloba, on Pneumocystis carinii. Antimicrob Agents Chemother. 1993 Jul;37(7):1492–1496. doi: 10.1128/aac.37.7.1492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dykstra C. C., Tidwell R. R. Inhibition of topoisomerases from Pneumocystis carinii by aromatic dicationic molecules. J Protozool. 1991 Nov-Dec;38(6):78S–81S. [PubMed] [Google Scholar]
  4. Edman J. C., Kovacs J. A., Masur H., Santi D. V., Elwood H. J., Sogin M. L. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature. 1988 Aug 11;334(6182):519–522. doi: 10.1038/334519a0. [DOI] [PubMed] [Google Scholar]
  5. Ezekowitz R. A., Williams D. J., Koziel H., Armstrong M. Y., Warner A., Richards F. F., Rose R. M. Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor. Nature. 1991 May 9;351(6322):155–158. doi: 10.1038/351155a0. [DOI] [PubMed] [Google Scholar]
  6. Gallant J. E., Moore R. D., Chaisson R. E. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med. 1994 Jun 1;120(11):932–944. doi: 10.7326/0003-4819-120-11-199406010-00006. [DOI] [PubMed] [Google Scholar]
  7. Hoshino H., Seki J., Takeuchi T. New antifungal antibiotics, benanomicins A and B inhibit infection of T-cell with human immunodeficiency virus (HIV) and syncytium formation by HIV. J Antibiot (Tokyo) 1989 Feb;42(2):344–346. doi: 10.7164/antibiotics.42.344. [DOI] [PubMed] [Google Scholar]
  8. Hughes W. T., Jacobus D. P., Canfield C., Killmar J. Anti-Pneumocystis carinii activity of PS-15, a new biguanide folate antagonist. Antimicrob Agents Chemother. 1993 Jul;37(7):1417–1419. doi: 10.1128/aac.37.7.1417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kimura S., Oka S., Mohri H., Mitamura K., Shimada K. Three cases of acquired immunodeficiency syndrome complicated with toxic epidermal necrolysis. Jpn J Med. 1991 Nov-Dec;30(6):553–558. doi: 10.2169/internalmedicine1962.30.553. [DOI] [PubMed] [Google Scholar]
  10. Kitada K., Oka S., Kimura S., Shimada K., Serikawa T., Yamada J., Tsunoo H., Egawa K., Nakamura Y. Detection of Pneumocystis carinii sequences by polymerase chain reaction: animal models and clinical application to noninvasive specimens. J Clin Microbiol. 1991 Sep;29(9):1985–1990. doi: 10.1128/jcm.29.9.1985-1990.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Klein N. C., Duncanson F. P., Lenox T. H., Forszpaniak C., Sherer C. B., Quentzel H., Nunez M., Suarez M., Kawwaff O., Pitta-Alvarez A. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS. 1992 Mar;6(3):301–305. doi: 10.1097/00002030-199203000-00007. [DOI] [PubMed] [Google Scholar]
  12. Lane H. C., Laughon B. E., Falloon J., Kovacs J. A., Davey R. T., Jr, Polis M. A., Masur H. NIH conference. Recent advances in the management of AIDS-related opportunistic infections. Ann Intern Med. 1994 Jun 1;120(11):945–955. doi: 10.7326/0003-4819-120-11-199406010-00007. [DOI] [PubMed] [Google Scholar]
  13. Masur H. Prevention and treatment of pneumocystis pneumonia. N Engl J Med. 1992 Dec 24;327(26):1853–1860. doi: 10.1056/NEJM199212243272606. [DOI] [PubMed] [Google Scholar]
  14. Phair J., Muñoz A., Detels R., Kaslow R., Rinaldo C., Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med. 1990 Jan 18;322(3):161–165. doi: 10.1056/NEJM199001183220304. [DOI] [PubMed] [Google Scholar]
  15. Sattler F. R., Cowan R., Nielsen D. M., Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med. 1988 Aug 15;109(4):280–287. doi: 10.7326/0003-4819-109-4-280. [DOI] [PubMed] [Google Scholar]
  16. Schmatz D. M., Romancheck M. A., Pittarelli L. A., Schwartz R. E., Fromtling R. A., Nollstadt K. H., Vanmiddlesworth F. L., Wilson K. E., Turner M. J. Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5950–5954. doi: 10.1073/pnas.87.15.5950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Takeuchi T., Hara T., Naganawa H., Okada M., Hamada M., Umezawa H., Gomi S., Sezaki M., Kondo S. New antifungal antibiotics, benanomicins A and B from an actinomycete. J Antibiot (Tokyo) 1988 Jun;41(6):807–811. doi: 10.7164/antibiotics.41.807. [DOI] [PubMed] [Google Scholar]
  18. Tanabe K., Takasaki S., Watanabe J., Kobata A., Egawa K., Nakamura Y. Glycoproteins composed of major surface immunodeterminants of Pneumocystis carinii. Infect Immun. 1989 May;57(5):1363–1368. doi: 10.1128/iai.57.5.1363-1368.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Tidwell R. R., Jones S. K., Naiman N. A., Berger L. C., Brake W. B., Dykstra C. C., Hall J. E. Activity of cationically substituted bis-benzimidazoles against experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1993 Aug;37(8):1713–1716. doi: 10.1128/aac.37.8.1713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Walzer P. D., Foy J., Steele P., White M. Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis. Antimicrob Agents Chemother. 1993 Jul;37(7):1436–1443. doi: 10.1128/aac.37.7.1436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Weinberg G. A. Iron chelators as therapeutic agents against Pneumocystis carinii. Antimicrob Agents Chemother. 1994 May;38(5):997–1003. doi: 10.1128/aac.38.5.997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wharton J. M., Coleman D. L., Wofsy C. B., Luce J. M., Blumenfeld W., Hadley W. K., Ingram-Drake L., Volberding P. A., Hopewell P. C. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med. 1986 Jul;105(1):37–44. doi: 10.7326/0003-4819-105-1-37. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES